Tempo reale
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
23,45 NOK | -0,85% | -1,88% | -44,17% |
Attività
Vendite per attività
NOK in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Enzymes
100,0
%
| 137 | 100,0 % | 119 | 100,0 % | -13,16% |
Vendite per regione
NOK in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
44,7
%
| 60 | 44,1 % | 53 | 44,7 % | -11,94% |
Lithuania
29,0
%
| 28 | 20,5 % | 35 | 29,0 % | +23,15% |
Other Countries in Europe
11,0
%
| 18 | 13,0 % | 13 | 11,0 % | -26,47% |
Germany
6,0
%
| 12 | 8,8 % | 7 | 6,0 % | -40,48% |
Rest of World
3,8
%
| 16 | 11,5 % | 5 | 3,8 % | -71,34% |
France
2,9
%
| - | - | 3 | 2,9 % | - |
Italy
2,4
%
| 3 | 1,9 % | 3 | 2,4 % | +9,83% |
Norway
0,2
%
| 0 | 0,3 % | 0 | 0,2 % | -48,86% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Michael Akoh
CEO | Chief Executive Officer | - | 18/09/23 |
Børge Sørvoll
DFI | Director of Finance/CFO | 49 | 01/10/14 |
Darren Ellis
CTO | Chief Tech/Sci/R&D Officer | - | 01/12/22 |
Chief Operating Officer | 56 | - | |
Olav Lanes
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/01/00 |
Dirk Hahneiser
SAM | Sales & Marketing | 56 | 01/01/22 |
Dino DiCamillo
SAM | Sales & Marketing | 66 | 01/01/12 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Olav Lanes
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/01/00 |
Chief Operating Officer | 56 | - | |
Bernd Striberny
BRD | Director/Board Member | - | - |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 50 871 390 | 35 904 791 ( 70,58 %) | 0 | 70,58 % |
Coordinate società
ArcticZymes Technologies ASA
Siva Innovasjonssenter Sykehusveien 23
9019, Tromsø
+47 77 64 89 00
http://www.arcticzymes.comSocietà del gruppo
Nome | Categoria e settore |
---|---|
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. |
Pharmaceuticals: Major
|
ArcticZymes AS
ArcticZymes AS Medical SpecialtiesHealth Technology Part of ArcticZymes Technologies ASA, ArcticZymes AS is a Norwegian company that manufactures diagnostic substances. The private company is based in Tromsø, Norway. Jethro Holter has been the CEO of the company since 2015. |
Medical Specialties
|
Settore
Vendite per attività
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-44,17% | 112 Mln | |
+29,77% | 49,46 Mrd | |
+1,00% | 42,58 Mrd | |
+49,90% | 42,49 Mrd | |
-5,26% | 29,09 Mrd | |
+13,68% | 26,61 Mrd | |
-22,99% | 18,64 Mrd | |
+8,22% | 13,16 Mrd | |
+32,41% | 12,55 Mrd | |
+24,01% | 12,1 Mrd |
- Borsa valori
- Azioni
- Azione AZT
- Società ArcticZymes Technologies ASA